Abeona Therapeutics Inc.
NASDAQ:ABEO
6.25 (USD) • At close November 1, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Abeona Therapeutics Inc. |
Symbool | ABEO |
Munteenheid | USD |
Prijs | 6.25 |
Beurswaarde | 270,715,000 |
Dividendpercentage | 0% |
52-weken bereik | 3.05 - 9.01 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Vishwas Seshadri M.B.A., Ph.D. |
Website | https://www.abeonatherapeutics.com |
An error occurred while fetching data.
Over Abeona Therapeutics Inc.
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)